Impairment

48 drugs in development·33 companies·1 clinical trial

Drug Pipeline by Phase

Approved(9)

Drug	Company
atomoxetine	Aptinyx Inc. (APTX)
atomoxetine	Teva Pharmaceutical Industries Limited (TEVA)
atomoxetine	DR REDDYS LABORATORIES LTD (RDY)
avlayah	Denali Therapeutics Inc. (DNLI)
dextroamp saccharate	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
fosinopril	Teva Pharmaceutical Industries Limited (TEVA)
Kisunla	ELI LILLY & Co (LLY)
neuraceq	Lantheus Holdings, Inc. (LNTH)
vizamyl	GE HealthCare Technologies Inc. (GEHC)

Phase 3(13)

Drug	Company
100 mg resmetirom	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
ads-5102	Adamas Pharmaceuticals Inc (ADMS)
AZD2693	ASTRAZENECA PLC (AZN)
BIIB080	BIOGEN INC. (BIIB)
canakinumab	Novartis AG (NVS)
Capivasertib	ASTRAZENECA PLC (AZN)
fazirsiran	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
fazirsiran	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
MK-8527	Merck & Co., Inc. (MRK)
mr-142	Viatris Inc (VTRS)
pelabresib	Novartis AG (NVS)
tazemetostat	Epizyme, Inc. (EPZM)
Treprostinil Palmitil	INSMED Inc (INSM)

Phase 2(10)

Drug	Company
200-1600 µg of mbx 2109 once-weekly by	MBX Biosciences, Inc. (MBX)
400 µg of mbx 2109 once-weekly by	MBX Biosciences, Inc. (MBX)
azd4144	ASTRAZENECA PLC (AZN)
canakinumab	Novartis AG (NVS)
mbx 2109	MBX Biosciences, Inc. (MBX)
nnc0194-0499	Novo Nordisk A/S (NVO)
nyx-458	Aptinyx Inc. (APTX)
ph15	Vistagen Therapeutics, Inc. (VTGN)
RL-007	Atai Beckley N.V. (ATAI)
sabirnetug (ACU193)	Acumen Pharmaceuticals, Inc. (ABOS)

Phase 1(8)

Drug	Company
amg 133	AMGEN INC (AMGN)
dazucorilant	CORCEPT THERAPEUTICS INC (CORT)
EDG-7500	Edgewise Therapeutics, Inc. (EWTX)
incb123667	Incyte Corp. (INCY)
LY3537031	ELI LILLY & Co (LLY)
mk4334	Neuphoria Therapeutics Inc. (NEUP)
Opemalirsen	ASTRAZENECA PLC (AZN)
pelabresib	Novartis AG (NVS)

Preclinical(2)

Drug	Company
ALPHA-1062 intranasal (ALPHA-1062IN)	Alpha Cognition Inc. (ACOG)
alpha-1062 sublingual	Alpha Cognition Inc. (ACOG)

Unknown(1)

Drug	Company
nb-02	MetaVia Inc. (MTVA)

Phase 1/Phase 2(1)

Drug	Company
Nemtabrutinib	Merck & Co., Inc. (MRK)

Phase 2/Phase 3(2)

Drug	Company
dalzanemdor	Sage Therapeutics, Inc. (SAGE)
nalbuphine er	Trevi Therapeutics, Inc. (TRVI)

Phase 4(2)

Drug	Company
metaxalone m640	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
tizanidine	ELITE PHARMACEUTICALS INC /NV/ (ELTP)

BioSniper tracks 48 drugs in development for Impairment across 33 companies.

There are 1 clinical trial targeting Impairment tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.